Search

Merck Immunotherapy Drug Shines In Lung Cancer Study

MERCK IMMUNOTHERAPY DRUG SHINES IN LUNG CANCER STUDY

Research finds that more than two-thirds of lung cancer patients who received Keytruda plus chemotherapy would be alive a year later,...

New immunotherapy drug becomes first ever to DOUBLE survival in lung cancer patients

NEW IMMUNOTHERAPY DRUG BECOMES FIRST EVER TO DOUBLE SURVIVAL IN LUNG CANCER PATIENTS

Merck's Keytruda, given with standard chemotherapy, cut in half the risk of dying or having the cancer worsen, compared to chemo alone...

 
 
 

IMMUNOGEN STOCK CLIMBS ON POSITIVE OVARIAN CANCER DATA

ImmunoGen, released positive efficacy and tolerability data from its FORWARD II trial of its mirvetuximab soravtansine in combination...

 
 
 
 
 
 
Roche Gains Ground on Rivals With Drug Combo's Success in Lung Cancer

ROCHE GAINS GROUND ON RIVALS WITH DRUG COMBO'S SUCCESS IN LUNG CANCER

Roche/Genentech reported this morning that its cancer immunotherapy drug, atezolizumab , has succeeded in a clinical study that could...

 
 
 
Immunotherapy Safety Worries Halt Celgene Myeloma Study, Slow 5 Others

IMMUNOTHERAPY SAFETY WORRIES HALT CELGENE MYELOMA STUDY, SLOW 5 OTHERS

Amid growing concerns about the safety of a new class of cancer immunotherapy drugs when combined with other therapies to treat blood...

 
 
 
Merck Drug Shows No Life-Extending Benefit in Head-and-Neck Cancer

MERCK DRUG SHOWS NO LIFE-EXTENDING BENEFIT IN HEAD-AND-NECK CANCER

The first immunotherapy approved in the U.S. to treat head and neck cancer has failed a big test, but it's unclear if the FDA will...

 
 
 
 
 
 
 
 
 
 
 
 
Merck raises its full-year forecast because one drug has been crushing it

MERCK RAISES ITS FULL-YEAR FORECAST BECAUSE ONE DRUG HAS BEEN CRUSHING IT

Thomson Reuters Merck & Co Inc reported a better-than-expected quarterly revenue, driven primarily by higher demand for its new cancer...